Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Common Equity (2020 - 2025)

Historic Common Equity for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $44.7 million.

  • Ovid Therapeutics' Common Equity fell 4141.04% to $44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.7 million, marking a year-over-year decrease of 4141.04%. This contributed to the annual value of $68.2 million for FY2024, which is 2229.12% down from last year.
  • Per Ovid Therapeutics' latest filing, its Common Equity stood at $44.7 million for Q3 2025, which was down 4141.04% from $55.8 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Common Equity peaked at $221.1 million during Q1 2021, and registered a low of $44.7 million during Q3 2025.
  • In the last 5 years, Ovid Therapeutics' Common Equity had a median value of $110.7 million in 2023 and averaged $120.4 million.
  • In the last 5 years, Ovid Therapeutics' Common Equity surged by 57811.6% in 2021 and then plummeted by 4141.04% in 2025.
  • Ovid Therapeutics' Common Equity (Quarter) stood at $179.7 million in 2021, then decreased by 26.41% to $132.3 million in 2022, then plummeted by 33.62% to $87.8 million in 2023, then decreased by 22.29% to $68.2 million in 2024, then tumbled by 34.49% to $44.7 million in 2025.
  • Its last three reported values are $44.7 million in Q3 2025, $55.8 million for Q2 2025, and $59.3 million during Q1 2025.